Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash from Financing Activities for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 99.84% to $73000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$336000.0, a 100.16% decrease, with the full-year FY2025 number at -$336000.0, down 100.16% from a year prior.
  • Cash from Financing Activities was $73000.0 for Q4 2025 at TScan Therapeutics, down from $116000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $161.6 million in Q2 2024 to a low of -$686000.0 in Q2 2021.
  • A 5-year average of $25.1 million and a median of $116000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 9060700.0% in 2021, then tumbled 303.49% in 2025.
  • TScan Therapeutics' Cash from Financing Activities stood at $120000.0 in 2021, then decreased by 10.0% to $108000.0 in 2022, then plummeted by 82.41% to $19000.0 in 2023, then soared by 240373.68% to $45.7 million in 2024, then crashed by 99.84% to $73000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Cash from Financing Activities are $73000.0 (Q4 2025), $116000.0 (Q2 2025), and -$525000.0 (Q1 2025).